特发性肺纤维化患者居家肺功能检测:INMARK 试验数据
基于 INMARK 试验,评估特发性肺纤维化(IPF)且 FVC 保留患者居家肺功能检测作为肺功能下降指标的可行性与有效性。346 例受试者随机接受尼达尼布或安慰剂 12 周,随后开放标签尼达尼布 40 周。居家肺功能检测可行且与门诊 FVC 强相关,但 FVC 下降速率的相关性较弱。
要点
- IPF 且 FVC 保留患者每周居家肺功能检测依从性 52 周平均 86%。
- 居家与门诊 FVC 各时间点强相关(r=0.72-0.84)。
- 居家与门诊估算的 52 周 FVC 下降速率相关性弱(r=0.26)。
核心结论
- 居家肺功能检测在 IPF 且 FVC 保留患者中是可行且有效的肺功能测量方法。
- 但居家肺功能检测估算的 FVC 下降速率与门诊肺功能检测估算值相关性差。
研究设计与样本
- INMARK 试验数据,IPF 且 FVC 保留受试者随机接受尼达尼布或安慰剂 12 周,随后开放标签尼达尼布 40 周。
- 共 346 例受试者接受治疗。
- 门诊肺功能检测于基线及第 4、8、12、16、20、24、36、52 周进行,居家肺功能检测要求至少每周一次、理想每日一次。
主要发现
- 每周居家肺功能检测依从性随时间下降,但每个 4 周期间均高于 75%,52 周平均依从性 86%。
- 居家肺功能检测的 FVC 较基线变化变异性大于门诊肺功能检测。
- 居家与门诊 FVC 在所有时间点强相关(r=0.72-0.84)。
- 居家与门诊估算的 FVC 变化速率相关性弱,52 周 FVC 下降速率 r=0.26。
关键数值与推荐
- 52 周平均居家肺功能检测依从性 86%。
- 每个 4 周期间居家肺功能检测依从性均高于 75%。
- 居家与门诊 FVC 各时间点相关 r=0.72-0.84。
- 52 周 FVC 下降速率居家与门诊相关 r=0.26。
临床怎么用
- 居家肺功能检测可用于 IPF 患者肺功能的可行监测,但不宜单独依据其估算 FVC 下降速率。
- 临床解读居家 FVC 下降速率时应谨慎,必要时结合门诊肺功能检测。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF). METHODS: Subjects with IPF and preserved forced vital capacity (FVC) were randomised to receive nintedanib or placebo for 12 weeks followed by open-label nintedanib for 40 weeks. Clinic spirometry was conducted at baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 52. Subjects were asked to perform home spirometry at least once a week and ideally daily. Correlations between home- and clinic-measured FVC and rates of change in FVC were assessed using Pearson correlation coefficients. RESULTS: In total, 346 subjects were treated. Mean adherence to weekly home spirometry decreased over time but remained above 75% in every 4-week period. Over 52 weeks, mean adherence was 86%. Variability in change from baseline in FVC was greater when measured by home rather than clinic spirometry. Strong correlations were observed between home- and clinic-measured FVC at all time-points (r=0.72-0.84), but correlations between home- and clinic-measured rates of change in FVC were weak (r=0.26 for rate of decline in FVC over 52 weeks). CONCLUSION: Home spirometry was a feasible and valid measure of lung function in patients with IPF and preserved FVC, but estimates of the rate of FVC decline obtained using home spirometry were poorly correlated with those based on clinic spirometry.
引用
- Noth I, Cottin V, Chaudhuri N, et al. Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. Eur Respir J. 2021. PMID: 33419890. doi:10.1183/13993003.01518-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。